These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31960603)

  • 41. Structure and Development of the List of Prohibited Substances and Methods.
    Kinahan A; Budgett R; Mazzoni I
    Med Sport Sci; 2017; 62():39-54. PubMed ID: 28571027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolonged stimulation of β
    Parichatikanond W; Nishimura A; Nishida M; Mangmool S
    J Pharmacol Sci; 2018 Nov; 138(3):184-191. PubMed ID: 30322801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance-enhancing drugs: understanding the risks.
    Hatton CK; Green GA; Ambrose PJ
    Phys Med Rehabil Clin N Am; 2014 Nov; 25(4):897-913. PubMed ID: 25442165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?
    Holimon TD; Chafin CC; Self TH
    Drugs; 2001; 61(3):391-418. PubMed ID: 11293649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urine concentrations of vilanterol and its metabolites, GSK932009 and GW630200, after inhalation of therapeutic and supratherapeutic doses.
    Østergaard M; Jessen S; Hansen ESH; Backer V; Panchal T; Baldwin S; Daley-Yates P; Hostrup M
    Drug Test Anal; 2023 May; 15(5):516-528. PubMed ID: 36610030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of beta2 agonists in sport: are the present criteria right?
    Naranjo Orellana J; Centeno Prada RA; Carranza Márquez MD
    Br J Sports Med; 2006 Apr; 40(4):363-6; discussion 366. PubMed ID: 16556795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Olodaterol and vilanterol detection in sport drug testing.
    Chundela Z; Große J
    Drug Test Anal; 2015; 7(11-12):980-2. PubMed ID: 26593301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
    Ryall JG; Sillence MN; Lynch GS
    Br J Pharmacol; 2006 Mar; 147(6):587-95. PubMed ID: 16432501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analytical strategy for detecting doping agents in hair.
    Thieme D; Grosse J; Sachs H; Mueller RK
    Forensic Sci Int; 2000 Jan; 107(1-3):335-45. PubMed ID: 10689585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation.
    Aziz I; McFarlane LC; Lipworth BJ
    Eur J Clin Pharmacol; 1999 Aug; 55(6):431-6. PubMed ID: 10492055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beta2-agonist eutomers: a rational option for the treatment of asthma?
    Boulton DW; Fawcett JP
    Am J Respir Med; 2002; 1(5):305-11. PubMed ID: 14720033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetic Effects of Inhaled Salbutamol on 10-km Time Trial Performance in Competitive Male and Female Cyclists.
    Koch S; MacInnis MJ; Rupert JL; Sporer BC; Koehle MS
    Clin J Sport Med; 2016 Mar; 26(2):145-51. PubMed ID: 25894531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List.
    Breenfeldt Andersen A; Jacobson GA; Bejder J; Premilovac D; Richards SM; Rasmussen JJ; Jessen S; Hostrup M
    Sports Med; 2021 Jul; 51(7):1353-1376. PubMed ID: 33811295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urine concentrations of repetitive doses of inhaled salbutamol.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1.
    Salomon JJ; Hagos Y; Petzke S; Kühne A; Gausterer JC; Hosoya K; Ehrhardt C
    Mol Pharm; 2015 Aug; 12(8):2633-41. PubMed ID: 25751092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The asthmatic athlete: inhaled Beta-2 agonists, sport performance, and doping.
    McKenzie DC; Fitch KD
    Clin J Sport Med; 2011 Jan; 21(1):46-50. PubMed ID: 21200170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 59. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
    Nikolopoulos DD; Spiliopoulou C; Theocharis SE
    Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effect of 1600 μg Inhaled Salbutamol Administration on 30 m Sprint Performance Pre and Post a Yo-Yo Intermittent Running Test in Football Players.
    Merlini M; Beato M; Marcora S; Dickinson J
    J Sports Sci Med; 2019 Dec; 18(4):716-721. PubMed ID: 31827356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.